POSITION PAPER

Improving vaccination rates in older adults and at-risk groups: focus on pertussis

Jung-Hyun Choi1 · Jaime Correia de Sousa2,3 · Monica Fletcher4 · Giovanni Gabutti5 · Lauriane Harrington6 · Michael Holden7 · Hyungwoo Kim6 · Jean-Pierre Michel8 · Piyali Mukherjee6 · Terry Nolan9 · Tobias Welte10,11 · Stefania Maggi12

Received: 8 September 2021 / Accepted: 24 October 2021 / Published online: 10 January 2022 © GlaxoSmithKline Biologicals S.A 2021

Abstract

Despite the implementation of effective paediatric vaccination programmes, pertussis remains a global health problem. Disease epidemiology has changed over time, shifting towards the adolescent and adult populations. In adults, the true burden of pertussis is greatly underestimated and pertussis vaccine coverage rates are suboptimal, including individuals with chronic conditions. Here, we report the outcomes of a virtual international scientific workshop to assess the evidence on the burden of pertussis in older adults and identify potential solutions to improve uptake of pertussis vaccines. In adults, pertussis is underdiagnosed in part due to atypical or milder clinical presentation and the lack of testing and case confirmation. However, contemporary epidemiological data denoted an increase in the burden of pertussis among adolescents and adults. This might be related to a variety of reasons including the waning of immunity over time, the lack of booster vaccination, and the improved diagnostic methods that led to increased recognition of the disease in adults. Pertussis sequelae can be severe in older adults, particularly those with existing chronic medical conditions, and the vulnerability of these groups is further enhanced by low pertussis vaccine coverage. Possible measures to increase vaccine uptake include strengthening and harmonisation of immunisation guidelines, healthcare professionals taking a more active role in recommending pertussis vaccination, involvement of vaccination centres and pharmacies in the vaccination process, and improving knowledge of pertussis burden and vaccine efficacy among the general population.

Keywords Pertussis · Vaccination · Tdap · Adults · Elderly · Risk group

Introduction

Pertussis is an infectious disease of the respiratory tract caused by the bacterium Bordetella pertussis [1]. Universal immunisation of the paediatric population has led to a significant decrease in disease-related incidence and mortality in infants [2, 3]. A resurgence of the disease has been observed in the last decade among adolescents and adults [4]. The World Health Organization (WHO) reported a total of 151,074 cases for 2018 across all ages,
along with a vaccination coverage of 86% in children [5]. In its annual epidemiological report, the European Centre for Disease Prevention and Control reported 35,627 pertussis cases for 2018, at an average incidence of 8.2 cases per 100,000 population. Sixty-two percent of cases were recorded in individuals ≥ 15 years of age [6]. Available evidence suggest that the burden of pertussis among older adults is greatly underestimated and underdiagnosed, and the real incidence of pertussis may be much higher than is reported [7, 8].

Adolescents and adults can be a source of transmission to infants who are too young to be fully vaccinated against pertussis and who are most susceptible to develop severe disease when infected. Previous studies have shown that household members, especially mothers, are the most common source of pertussis infection in infants less than 6 months old [9, 10]. Maternal immunisation has a key role and is highly effective for prevention of pertussis in newborns and young infants [11, 12]. Healthcare workers who are not protected against pertussis are at high risk for *B. pertussis* exposure and infection and can also transmit the disease to susceptible patients [13, 14].

Adult vaccination strategies against pertussis might be the most effective measure to not only protect the individuals from the disease and its complications, but also mount an indirect protection of new-born infants through immunisation of parents, older siblings, and healthcare workers [9, 15].

Combination vaccines containing reduced-antigen-content tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) are currently widely available for vaccination of children, adolescents and adults [16]. The safety and immunogenicity of Tdap vaccines has been confirmed by numerous clinical trials [17–21], and decennial booster vaccination programmes are now recommended in several countries [22, 23].

The coronavirus disease (COVID-19) pandemic has highlighted the value of vaccination of vulnerable adult populations as a preventive measure against infectious diseases. The International Council on Adult Immunization stressed the urgent need for global adult immunisation strategy that covers available vaccines against a variety of pathogens other than the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and called upon global community and various stakeholders to implement evidence-based adult immunisation programmes and policies [24].

The authors, stakeholders, and experts in the field of adult vaccination from multiple countries (Australia, Belgium, Germany, Italy, Portugal, South Korea, Switzerland, and United Kingdom) gathered during a virtual scientific workshop organised by GSK on the 30th of June 2020. The objectives were to (1) assess the evidence on the burden of pertussis in older adults and those with respiratory conditions and (2) identify solutions to improve uptake of Tdap vaccines. This manuscript summarises those discussions. A lay language graphical summary is also available in Fig. 1.

**Pertussis epidemiology: not just a childhood disease**

Adults > 18 years of age are now proportionally more affected by pertussis than 10–20 years earlier [7, 8, 25]. In Sweden, 59% of the total laboratory-confirmed pertussis cases were reported for adults > 18 years old in 2018 as compared with 4% of cases reported in 1998. Among older adults > 50 years of age, these rates were 17.3% (2018) compared with 1.3% (1998) [26]. Similar trends have been observed in Germany [27] and Australia [28]. This resurgence can be attributed to several factors such as low vaccine coverage, waning immunity, and lack of booster vaccination,
but also improving diagnostic methods and increasing recognition of the disease in adults [3, 29].

Immune responses against pertussis, whether natural or acquired through vaccination, decline over time [30]. Booster vaccinations to maintain high antibody levels are needed for the prevention of the disease [3]. Although slight fluctuations of the worldwide vaccination coverage in children have occurred, it has been estimated at 81.6% in 2019 [31]; however, vaccination coverage among adults is low. It has been estimated that about 4.1 million Australians are not vaccinated under the National Immunisation Program each year [32]. Similarly, Tdap vaccination coverage among adults aged ≥ 19 years in the United States (US) was 31.7% in 2017 [33]. Limited access to vaccines, lack of provider recommendations, low public awareness of pertussis and the benefits of vaccination, misinformation, and fear of vaccines’ side effects are potential reasons behind this low coverage. From the healthcare practitioners’ (HCPs) perspective, patients forgetting about their appointments, inadequate access to vaccination and language barriers, are perceived as major barriers for vaccine acceptance [34].

Burden of pertussis in adults

Today, the demographic dispersion of pertussis includes adolescents and adults, in addition to infants. Furthermore, the true burden of pertussis in adolescents and adults is greatly underestimated [8, 35].

One factor of underestimation is related to the atypical clinical characteristics of cases compared to the classical child symptoms, making the diagnosis difficult [36]. After the incubation period, the typical pertussis infection course starts with a catarrhal stage, during which symptoms closely resemble a mild upper respiratory tract infection, followed by a paroxysmal stage and convalescent stage [1, 37]. During the paroxysmal stage, children experience intense and violent coughing that last several minutes and is accompanied with a whooping sound when breathing in. Although adolescents and adults present similar symptoms, these might be milder than in children, resulting in failure to diagnose or misdiagnosis. According to a recent systematic review, paroxysmal cough, inspiratory whooping and post-tussive vomiting are the three most common clinical features of pertussis in adults that can be considered by physicians for the clinical diagnosis of the disease [38]. In a study of 27 adolescents and adults, all individuals had paroxysmal cough, 26% had whooping, and 56% had post-tussive vomiting [39]. The complications of coughing can include urinary incontinence (mainly reported in women), fainting, and rib fractures. Many others clinical features are classically reported as pharyngeal, influenza-like symptoms, sinus pain, sneezing attacks, hoarseness, headaches, and sweating attacks [36, 40].

Besides atypical presentation of pertussis in older adults, late presentation to HCPs (leading to no or late testing) contribute to under-diagnosis of the disease in this age group. Given the limited sensitivity of laboratory diagnostic methods, there is a need for more and earlier testing of patients presenting with a cough. Awareness of the symptoms of pertussis (including atypical ones) in adults and of the time-sensitivity of laboratory testing needs to increase.

Another cause of underestimation is the challenge associated with laboratory case confirmation. Culture of nasopharyngeal secretions and polymerase chain reaction are traditionally used for diagnosis but are effective only at the early phase of the disease. Patients, however, may present late to HCPs and it typically takes several visits to reach a diagnosis. Serologic testing targets pertussis toxin, but results can be affected by pre-existing immunity (induced either by previous vaccination or infection). Moreover, serologic methods for the diagnosis of pertussis are not standardised [41].

An additional concern of geriatricians is the possible links of B. pertussis with dementia. This is based on the well-established correlation existing between systemic inflammation and Alzheimer disease (AD) and accounts one intriguing epidemiologic observation [42]. The subclinical nasopharyngeal B. pertussis colonisation, in close proximity to the central nervous system and olfactory pathway, could explain how B. pertussis and its toxin account for the activation of the microglia, inflammation, atrophy, and accumulation of the amyloid plaques and tau tangles in the brain [43].

In addition, vaccination against pertussis has been associated with a significantly reduced risk for AD [43]. While this new hypothesis of the potential involvement of B. pertussis in the aetiology of AD is still the topic of ongoing debates, in a life-course perspective, the important role of infant vaccinations and boosters later in life is well-established.

During the workshop, extensive discussions were conducted on the long-term consequences of pertussis and the increased impact from comorbidities. The clinical course and the potential complications and sequelae of the disease may also be severe among older adults, not just in infants. Studies suggest that older adults have an increased risk for pertussis-related mortality than children or adolescents, though it is likely to be underestimated [8]. Complications, such as apnoea, pneumonia, sinusitis, and otitis media also increases with age [8, 44]. Other complications are less frequent and include seizures and encephalopathy (cerebral hypoxia related to asphyxia), subarachnoid and intraventricular haemorrhages, and tetanic seizures [45]. Individuals with underlying conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and obesity are at an even higher risk to develop a severe form of the disease [46–48].
and recent studies suggest that pertussis incidence in COPD populations may be grossly underestimated [49, 50]. Pertussis has been associated with an increase in healthcare resource use in patients with COPD and asthma, increasing the overall economic burden, exacerbation, and hospitalisation rate related to the disease [51–53].

The COVID-19 pandemic has highlighted the vulnerability of older adults to respiratory infectious diseases and their complications. It has been revealed that individuals with comorbidities are more vulnerable to infection and are more prone to develop severe symptoms. Some of the most common comorbidities in hospitalised COVID-19 patients with comorbidities are more vulnerable to infection and are associated with an increased risk of pertussis infection in adults.

**Immunisation strategies for adults**

Vaccination is one of the most effective strategies to prevent infection and reduce severity of pertussis in adolescents and adults [1]. Antibodies against *B. pertussis* antigens play a fundamental role in the protection against pertussis. There is, however, no correlate of protection, meaning that antibody levels cannot be precisely correlated with clinical protection [56]. Tdap vaccines have been demonstrated to be well tolerated and highly immunogenic in adults [57]. Although immune responses against pertussis antigens decline over time, they remain several fold higher than pre-vaccination levels for 10 years after booster vaccination. The decennial booster dose mounts a strong anamnestic response for all tested pertussis antigens. Although injection site reactions are common, the vaccine is generally well tolerated [18, 21, 30, 58].

Since 2005, the US Advisory Committee on Immunization Practices recommended vaccination with one dose of Tdap for previously unvaccinated adolescents aged 11–18 years and adults aged 19–64 years. This recommendation was expanded to adults aged > 65 years in 2012 [59]. The 2011 updates of the recommendation also included the immunisation of unvaccinated pregnant women and all household contacts of newborns who had not been vaccinated [60]. Since 2019, adolescents aged > 11 years and adults who have never been vaccinated with Tdap before, should receive one dose as soon as possible, followed by another two doses (Td or Tdap) at 4 weeks and 6–12 months after the first dose. Thereafter, a booster dose should be administered every 10 years [61]. Healthcare workers in close contact with patients should also receive a Tdap dose [62]. In the United Kingdom, routine immunisation against pertussis does not include adolescents ≥ 10 years of age and adults, except for pregnant women and during outbreaks [63]. However, a booster dose is recommended for healthcare personnel working with infants if they did not receive a dose in the preceding 5 years [64]. National policies for the immunisation of healthcare workers against pertussis are in place in 19 other European countries [65]. Maternal immunisation as well as a decennial booster with Tdap is also recommended in several European countries [22].

**Strategies to improve adult vaccination coverage**

In contrast with the fairly high vaccination coverage achieved in children, that is currently hampered by the COVID-19 pandemic [66], optimisation of adult vaccination was not successfully accomplished in any country until now, resulting in a worldwide under-immunisation of this age group.

During the COVID-19 pandemic, most national and international agencies, such as the WHO, the Centers for Disease Control (CDC), the Robert Koch Institute, and the Italian public health authority have all reinforced their recommendations on adult vaccination, including Tdap, to help protect HCPs and the residents of care facilities, and to reduce the risk of double infection, the number of possible clinical visits, and the difficulties related to differential diagnosis of COVID-19 and other respiratory infections with similar clinical features [67–70]. This may generate a shift in attitude and awareness of vaccine preventable diseases in both HCPs and the public.

There are multiple barriers found at the patient, HCP, infrastructure, and funding level that prevent reaching a high vaccine uptake among adults. The belief by some HCPs and patients that childhood vaccination provides lifelong protection, the low awareness of pertussis as an adult disease, as well as the low awareness of safety and benefits of adult pertussis vaccines might lead to lack of recommendation among HCPs and to vaccine hesitancy or refusal among patients [34, 71]. Extensive education on the disease and the value of vaccination initiatives would raise awareness of the benefits of adult vaccination. Even when vaccination is recommended, coverage rates in adults are low, highlighting that public health authority recommendation is not sufficient. As shown in different studies, HCP recommendations may increase vaccine uptake in their adult patients [32, 72]. Thus, vaccination needs to be part of the HCP’s care plan for patients and cover all adult vaccines.

Implementation of vaccination programmes for high-risk adults is even more troublesome, likely due to difficulties in identifying and reaching out to these people. Disparities of recommendations in different countries may impede efforts to improve adult vaccination. International guidelines would create a harmonised recommendation for adult vaccination.

The vaccination process involves many stakeholders: general practitioners, nurses, pharmacists, geriatricians, specialists (e.g. pulmonologists for asthma and COPD), and

 Springer
funding bodies. Cooperation across disciplines and societies could improve pertussis awareness and adult vaccination compliance. Vaccination centres other than primary care providers, such as community pharmacies can be an attractive channel and be an efficient way to improve vaccine access and coverage among adults [73, 74]. People visit the pharmacist four times more often than other HCPs, pharmacies are already involved in dispensing vaccines, and some countries have legislation allowing vaccination at the pharmacy [75]. During the 2014/2015 and 2015/2016 influenza seasons, 115,000 doses of influenza vaccine were delivered in pharmacies in Ireland; this represents about 10% of all administered influenza vaccines. During the 2020/21 influenza season, community pharmacies in England delivered 2.6 million doses of influenza vaccine, which is 53% higher compared to the 2019/20 season, and are also supporting the COVID-19 vaccination programme [76]. In countries where pharmacy vaccination was introduced (Canada, the US, Portugal), flu vaccine coverage increased [75].

Waning of immunity, immunosenescence, and burden of pertussis in adults provide a strong rational for booster vaccination, considering immunogenicity and safety of Tdap. It might have better acceptance among older adults than the concomitant administration of Td and monovalent pertussis vaccines. Implementation of Tdap for the decennial booster might also be cost-effective [77]. Randomised clinical trials designed to establish Tdap efficacy in the older adults are still needed, however, the effectiveness of Tdap vaccination has been demonstrated in older adults [78].

Tdap vaccination in the COVID-19 era was also discussed during the workshop. On one hand, despite the value of adult vaccination being reinforced both by the current pandemic situation and by several international and national recommendations, less funding is likely to be directed towards the diagnosis of pertussis and Tdap vaccination in the near future. On the other hand, disease severity and the high morbidity and mortality observed among older adults and at-risk populations during the COVID-19 pandemic may redound to adult vaccination efforts and direct more attention towards protection of adults and at-risk groups. As pertussis is difficult to diagnose and it could increase the risk of hospitalisation in adults [79], vaccination may also have the potential to relieve pressure on healthcare systems in difficult times. The role of pharmacists in immunisation programmes would be even more important while the SARS-CoV-2 is still circulating, though comprehensive training programmes are required for them to be able to administer vaccines where this is not a standard. Finally, there is an increased public awareness of respiratory infectious disease, even among patients, but fear of COVID-19 may drop willingness to attend primary healthcare sites for vaccination.

Conclusions

Pertussis is still a frequent infectious disease, with high burden among adolescents and adults, particularly for those with underlying health conditions. This adult population represents a significant source of transmission for unvaccinated or partially vaccinated infants. Atypical clinical presentation of pertussis in adolescents and adults makes clinical diagnosis difficult. Despite recent improvements, a more accurate epidemiological surveillance is desirable to assess the real burden of disease and the impact of vaccination. Pertussis control in older adults could be improved by engaging scientific leaders for a multidisciplinary approach of pertussis and its complications, obtaining a political commitment for the need of research and long-term vaccination policies, and by creating a dialogue on the value of vaccination to increase public engagement.

Acknowledgements The authors thank Yan Sergerie for his valuable input during the development of the manuscript. They also thank the Modis platform, on behalf of GSK, for editorial assistance and manuscript coordination. Medical writing services were provided by Botond Nagy and publication coordination were provided by Ivana Lesnjak.

Author contributions All the authors attended the workshop, reviewed, and approved the manuscript prior to submission.

Funding Open access funding provided by University of Geneva. GlaxoSmithKline Biologicals SA funded the workshop and took responsibility for all costs associated with the development of the present manuscript.

Availability of data and material Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest LH, PM, and HK are employees of the GSK group of companies. PM report ownership of shares and/or restricted shares of the GSK group of companies. TN reports personal fees from GSK during the conduct of the study and personal fees from GSK, outside the submitted work. GG reports personal fees from GSK, Sanofi Pasteur Italy, MSD, Merck, Pfizer, Seqirus and Emergent Biosolutions, outside the submitted work. SM reports grants from GSK, MSD, Takeda and Sanofi, and personal fees from GSK, outside the submitted work. HK reports other relationships with GSK, during the conduct of the study. TW reports grants from the German Ministry of Research and Education, and personal fees from GSK, MSD, AstraZeneca, Biogen, Pfizer, Johnson & Johnson, during the conduct of the study. JcDs reports personal fees from AstraZeneca and Mundipharma, non-financial support from AstraZeneca and other relationships with Boehringer Ingelheim, GSK, AstraZeneca, Mundipharma, Bial and Novartis, outside the submitted work. JHC, MF, MH and JPM have nothing to disclose.

Ethical approval Not applicable.

Human and animal rights Not applicable.
References

1. Centers for Disease Control and Prevention (CDC) (2021) Pertussis (whooping cough). https://www.cdc.gov/pertussis/about/index.html. Accessed 17 Feb 2021
2. Htar MTT, de Ridder M, Braeye T et al (2020) Advance system testing: vaccine benefit studies using multi-country electronic health data: the example of pertussis vaccination. Vaccine 38:B31–B37. https://doi.org/10.1016/j.vaccine.2019.08.078
3. World Health Organization (WHO) (2021) Pertussis vaccines—WHO position paper 2015. https://www.who.int/publications/i/item/who-position-paper-pertussis-vaccines. Accessed 18 Feb 2021
4. European Centre for Disease Prevention and Control (2021) Surveillance Atlas of infectious diseases. http://atlas.ecdc.europa.eu/public/index.aspx. Accessed 17 Feb 2021
5. World Health Organization (WHO) (2021) Pertussis. https://www.who.int/health-topics/pertussis#tab=tab_1. Accessed 17 Feb 2021
6. European Centre for Disease Prevention and Control (2020) Pertussis. Annual epidemiological report for 2018. https://www.ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2018. Accessed 12 Feb 2021
7. Gabutti G, Rota MC (2012) Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health 9:4626–4638. https://doi.org/10.3390/ijerph9124626
8. Kandeil W, Atanasov P, Avramioti D et al (2019) The burden of pertussis in older adults: what is the role of vaccination? A systematic review. Drug Saf 27:105–114. https://doi.org/10.1007/s40264-019-00831-5
9. Munoz FM, Bond NH, Maccato M et al (2014) Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 311:1760–1769. https://doi.org/10.1001/jama.2014.3633
10. Halperin SA, McNeil S, Langley J et al (2011) Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose. Vaccine 29:8459–8465. https://doi.org/10.1016/j.vaccine.2011.07.068
11. Halperin SA, Donovan C, Marshall GS et al (2019) Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose. J Pediatr Infect Dis Soc 8:105–114. https://doi.org/10.1093/jpids/pix113
12. Abu-Rowa A, Maertens K, Edwards KM et al (2020) Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement. Front Immunol 11:1282. https://doi.org/10.3389/fimmu.2020.01282
13. Kuncio DE, Middleton M, Cooney MG et al (2014) Health care worker exposures to pertussis: missed opportunities for prevention. Pediatrics 133:15–21. https://doi.org/10.1542/peds.2013-0745
14. Sandora TJ, Gidengil CA, Lee GM (2008) Pertussis vaccination for health care workers. Clin Microbiol Rev 21:426–434. https://doi.org/10.1128/cmrr.00003-08
15. Blangiardi F, Ferrera G (2009) Reducing the risk of pertussis in newborn infants. J Prev Med Hyg 50:206–216
16. European Medicines Agency (2017) List of nationally authorised medicinal products. Active substance(s): diphtheria / tetanus / pertussis (acellular, component) vaccine (adsorbed), diphtheria / tetanus / pertussis (acellular, component) vaccine (adsorbed) reduced antigens contents. https://www.ema.europa.eu/en/documents/psusa/diphtheria/tetanus/pertussis-acellular-component-vaccine-adsorbed-diphtheria-tetanus-pertussis-acellular-component-vaccine-adsorbed-reduced-antigens-contents-list-nationally-authorised_en.pdf. Accessed 22 Nov 2020
17. Halperin SA, McNeil S, Langley J et al (2011) Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose. Vaccine 29:8459–8465. https://doi.org/10.1016/j.vaccine.2011.07.068
18. Halperin SA, Donovan C, Marshall GS et al (2019) Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose. J Pediatr Infect Dis Soc 8:105–114. https://doi.org/10.1093/jpids/pix113
19. Munoz FM, Bond NH, Maccato M et al (2014) Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 311:1760–1769. https://doi.org/10.1001/jama.2014.3633
20. Jackson ML, Yu O, Nelson JC et al (2018) Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Pharmacoepidemiol Drug Saf 27:921–925. https://doi.org/10.1002/pds.4569
21. Kovac M, Kostanyan L, Mesaros N et al (2018) Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: an open, phase III, non-randomized, multi-center study. Hum Vaccin Immunother 14:1977–1986. https://doi.org/10.1080/21645515.2018.1460929
22. European Centre for Disease Prevention and Control (2021) Vaccine schedules in all countries of the European Union. https://vaccine-schedule.ecdc.europa.eu/. Accessed 22 Mar 2021
23. Havers FP, Moro PL, Hunter P et al (2020) Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices-United States, 2019. MMWR Morb Mortal Wkly Rep 69:77–83. https://doi.org/10.15585/mmwr.mm6903a5
24. Privor-Dumm LA, Poland GA, Barratt J et al (2020) A global agenda for older adult immunization in the COVID-19 era: a roadmap for action. Vaccine. https://doi.org/10.1016/j.vaccine.2020.06.082
25. Gabutti G, Azzari C, Bonanni P et al (2015) Pertussis. Hum Vaccin Immunother 11:108–117. https://doi.org/10.4161/hvi.34364
26. Public Health Agency of Sweden (2018) Pertussis surveillance in Sweden. 21st annual report. https://www.folkhalsomyndigheten.se/contentassets/cd49f11f96f4e6a8db3234fbb9da8b8/0/pertussis-surveillance-sweden-twenty-first-report-19071.pdf. Accessed 22 Feb 2021
27. SurvStat@RKI 2.0 (2021). https://survstat.rki.de/Content/Query/Create.aspx. Accessed 22 Mar 2021
28. National Notifiable Diseases Surveillance System (2021). http://www9.health.gov.au/cda/source/rpt_5_sel.cfm. Accessed 22 Mar 2021

29. Ring N, Abrahams JS, Bagby S et al (2019) How genomics is changing what we know about the evolution and genome of Bordetella pertussis. Adv Exp Med Biol 1183:1–17. https://doi.org/10.1007/5584_2019_401

30. Pool V, Tomovici A, Johnson DR et al (2018) Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, pertussis, and 5-component acellular pertussis vaccine in the USA. Vaccine 36:2282–2287. https://doi.org/10.1016/j.vaccine.2018.03.029

31. Galles NC, Liu PY, Updike RL et al (2021) Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. The Lancet 398:503–521. https://doi.org/10.1016/S0140-6736(21)00984-3

32. Menzies RI, Leask J, Royle J et al (2017) Vaccine myopia: adult vaccination coverage among Adults in the United States, National Health Interview Survey. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html. Accessed 17 Feb 2021

33. Centers for Disease Control and Prevention (CDC) (2017) Vaccination coverage among Adults in the United States, National Health Interview Survey. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html. Accessed 17 Feb 2021

34. Royal Society for Public Health (2021) Moving the needle: promoting vaccination uptake across the life course. https://www.rsp.org.uk/static/uploaded/3b82db00-a7ef-494c-85451e78ce18a779.pdf. Accessed 12 Feb 2021

35. Nunes A, Abreu A, Furtado B et al (2021) Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review. Hum Vacc Immunother 17:1733–1746. https://doi.org/10.1007/s40121-016-00167

36. Zycinska K, Cieplak M, Chmielewska M et al (2017) Whooping cough in adults: a series of severe cases. Adv Exp Med Biol 955:47–50. https://doi.org/10.1016/j.chem.2018.09.027

37. Tozzi AE, Celentano LP, Atti MLC et al (2005) Diagnosis and management of pertussis. CMAJ 172:509–515. https://doi.org/10.1503/cmaj.1040766

38. Moore A, Harnden A, Grant CC et al (2019) Clinically diagnosing pertussis-associated cough in adults and children: CHEST guideline and expert panel report. Chest 155:147–154. https://doi.org/10.1016/j.chest.2018.09.027

39. Strebel P, Nordin J, Edwards K et al (2001) Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. J Infect Dis 183:1353–1359. https://doi.org/10.1086/319853

40. Postels-Multani S, Wissing von König CH, Schmitt HJ et al (1995) Symptoms and complications of pertussis in adults. Infection 23:139–142. https://doi.org/10.1007/BF01793853

41. van der Zee A, Schellekens JFP, Mooi FR (2015) Laboratory diagnosis of pertussis. Clin Microbiol Rev 28:1005–1026. https://doi.org/10.1128/CMR.00031-15

42. Sochocka M, Zwisolka K, Leszek J (2017) The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol 15:996–1009. https://doi.org/10.2174/1570159X15666170313122937

43. Rubin K, Glazer S (2017) The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer’s disease. Immunobiology 222:228–240. https://doi.org/10.1016/j.imbio.2016.09.017

44. Kilgore PE, Salim AM, Zervos MJ et al (2016) Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 29:449–486. https://doi.org/10.1128/cmr.00083-15

45. Sanghi V (2014) Neurologic manifestations of diphtheria and pertussis. Handb Clin Neurol 121:1355–1359. https://doi.org/10.1016/b978-0-7020-4088-7.00092-4

46. Mbayei SA, Faulkner A, Miner C et al (2017) Severe pertussis infections in the United States, 2011–2015. Clin Infect Dis 69:218–226. https://doi.org/10.1093/cid/ciy889

47. Liu BC, McIntyre P, Kaldor JM et al (2012) Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis 55:1450–1456. https://doi.org/10.1093/cid/cis627

48. Jenkins VA, Savic M, Kandeil W (2020) Pertussis in high-risk groups: an overview of the past quarter-century. Hum Vacc Immunother 16:2699–2617. https://doi.org/10.1007/21645515.2020.1738168

49. Aris E, Harrington L, Bhavsar A et al (2021) Burden of pertussis in COPD: a retrospective database study in England. COPD 18:157–169. https://doi.org/10.1080/15412555.2021.1899155

50. Wilkinson TMA, Van den Steen P, Cheuvart B et al (2021) Seroprevalence of Bordetella pertussis infection in patients with chronic obstructive pulmonary disease in England: analysis of the AERIS Cohort. COPD 18:341–348. https://doi.org/10.1080/15412555.2021.1920904

51. Blasi F, Bonanni P, Braido F et al (2020) The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. Hum Vacc Immunother 16:340–348. https://doi.org/10.1007/21645515.2019.652517

52. Buck PO, Meyers JL, Gordon LD et al (2017) Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect 145:2109–2121. https://doi.org/10.1017/S0950268817000887

53. Macina D, Evans KE (2021) Pertussis in individuals with comorbidities: a systematic review. Infect Dis Ther 10:1141–1170. https://doi.org/10.1007/s40121-021-00465-z

54. Karagiannis C, Mostert C, Henschker C et al (2020) Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 8:853–862. https://doi.org/10.1016/s2213-2600(20)30316-7

55. Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323:2052–2059. https://doi.org/10.1001/jama.2020.6775

56. Kapil P, Merkel TJ (2019) Pertussis vaccines and protective immunity. Curr Opin Immunol 59:72–78. https://doi.org/10.1016/j.coi.2019.03.006

57. Xu J, Liu S, Liu Q et al (2019) The effectiveness and safety of pertussis booster vaccination for adolescents and adults: a systematic review and meta-analysis. Medicine (Baltimore) 98:e15281. https://doi.org/10.1097/md.00000000000015281

58. Booy R, Van der Meeren O, Ng SP et al (2010) A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (BoostrixTM) is immunogenic and well tolerated in adults. Vaccine 29:45–50. https://doi.org/10.1016/j.vaccine.2010.10.025

59. Centers for Disease Control and Prevention (CDC) (2012) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 61:468–470

60. Centers for Disease Control and Prevention (CDC) (2011) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60:1424–1426
61. Centers for Disease Control and Prevention (CDC) (2021) Recommended adult immunization schedule for ages 19 years or older, United States, 2021. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html#note-tdap. Accessed 29 Mar 2021

62. Centers for Disease Control and Prevention (CDC) (2021) Pertussis: summary of vaccine recommendations. https://www.cdc.gov/vaccines/vpd/pertussis/recs-summary.html. Accessed 18 Feb 2021

63. Public Health England (2013) UK immunisation schedule: the green book. chapter 11. https://www.gov.uk/government/publications/immunisation-schedule-the-green-book-chapter-11. Accessed 29 Mar 2021

64. Public Health England (2012) Public health management of pertussis in healthcare settings. https://www.gov.uk/government/publications/pertussis-guidelines-for-public-health-management-in-a-healthcare-setting. Accessed 29 Mar 2021

65. Maltezou HC, Botelho-Nevers E, Brantsæter AB et al (2019) Vaccination of healthcare personnel in Europe: update to current policies. Vaccine 37:7576–7584. https://doi.org/10.1016/j.vaccine.2019.09.061

66. Causey K, Fullman N, Sorensen RJD et al (2021) Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study. Lancet 398:522–534. https://doi.org/10.1016/S0140-6736(21)01337-4

67. Centers for Disease Control and Prevention (CDC) (2020) Interim guidance for routine and influenza immunization services during the COVID-19 pandemic. (2020). https://www.cdc.gov/vaccine/pandemic-guidance/index.html. Accessed 22 Feb 2021

68. Institut RK (2021) Empfehlungen der Ständigen Impfkommission. https://www.rki.de/DE/Content/Kommissionen/STIKO/Impfehlungen/Impfempfehlungen_node.html. Accessed 29 Mar 2021

69. Bonanni P, Villani A, Scotti S et al (2021) The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: a continuing example of impact on public health policies. Vaccine 39:1183–1186. https://doi.org/10.1016/j.vaccine.2021.01.019

70. World Health Organization (WHO) (2021) Routine immunization services during the COVID-19 pandemic. https://apps.who.int/iris/handle/10665/331925. Accessed 22 Feb 2021

71. Martinón-Torres F, Heininger U, Thomson A et al (2018) Controlling pertussis: how can we do it? A focus on immunization. Expert Rev Vaccines 17:289–297. https://doi.org/10.1080/14760584.2018.1445530

72. Bayliss J, Randhawa R, Oh KB et al (2021) Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussis. Hum Vacc Immunother 17:344–350. https://doi.org/10.1080/21645515.2020.1780848

73. Gauld N, Johnstone E, McMichael I et al (2021) Pharmacists’ views and desires regarding pharmacist administration of vaccines in New Zealand. Int J Pharm Pract 29:126–133. https://doi.org/10.1093/ippr/aia012

74. Mills B, Fensterheim L, Taitel M et al (2014) Pharmacist-led Tdap vaccination of close contacts of neonates in a women’s hospital. Vaccine 32:521–525. https://doi.org/10.1016/j.vaccine.2013.11.035

75. Rosado H, Bates I, Pyzik O, Pinto G, Besançon L (2016) An overview of current pharmacy impact on immunisation A global report 2016. The Hague: International Pharmaceutical Federation. https://www.fip.org/files/fip/publications/FIP_report_on_Immunisation.pdf. Accessed 17 Feb 2021

76. Pharmaceutical Services Negotiating Committee (2021) Flu vaccination data for 2019/20. https://psnc.org.uk/services-consulting/advanced-services/flu-vaccination-service/flu-vaccination-statistics/flu-vaccination-data-for-2019-20/. Accessed 12 Feb 2021

77. Havers FP, Cho B-H, Walker JW et al (2020) Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States. Vaccine 38:380–387. https://doi.org/10.1016/j.vaccine.2019.09.104

78. Liu BC, He WQ, Newall AT et al (2020) Effectiveness of acellular pertussis vaccine in older adults: nested matched case-control study. Clin Infect Dis 71:340–350. https://doi.org/10.1093/cid/ciz821

79. Karki S, McIntyre P, Newall AT et al (2015) Risk factors for pertussis hospitalizations in Australians aged 45 years and over: a population based nested case-control study. Vaccine 33:5647–5653. https://doi.org/10.1016/j.vaccine.2015.08.068

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.